Recent SAGE News
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 04/25/2024 10:30:00 AM
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease • Business Wire • 04/17/2024 10:30:00 AM
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/11/2024 10:30:00 AM
- Sage Therapeutics to Present at Upcoming March Investor Conferences • Business Wire • 02/28/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/21/2024 09:35:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:15 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:09:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/14/2024 12:49:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/14/2024 12:20:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 11:45:53 AM
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 02/14/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 01/31/2024 10:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:50:55 PM
- Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 • Business Wire • 01/31/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:10:55 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 01/23/2024 01:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:45:04 AM
- Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2024 11:32:00 AM
- Sage Therapeutics Announces Changes to Board of Directors • Business Wire • 01/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:07:58 PM
- Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 • Business Wire • 01/02/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/19/2023 01:32:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/19/2023 01:30:28 PM
- ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. • GlobeNewswire Inc. • 12/14/2023 11:30:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM